Total Payments
$626.34
2024 Payments
$192.33
Companies
17
Transactions
30
Medicare Patients
15,596
Medicare Billing
$2.8M
Payment Breakdown by Category
Food & Beverage$597.36 (95.4%)
Education$28.98 (4.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $597.36 | 28 | 95.4% |
| Education | $28.98 | 2 | 4.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $136.72 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $66.16 | 3 | $0 (2024) |
| Seagen Inc. | $66.05 | 3 | $0 (2023) |
| PharmaEssentia USA Corporation | $58.64 | 2 | $0 (2024) |
| Eisai Inc. | $41.19 | 2 | $0 (2020) |
| PFIZER INC. | $38.13 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $31.92 | 2 | $0 (2021) |
| Lilly USA, LLC | $26.85 | 1 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.77 | 1 | $0 (2018) |
| Genentech USA, Inc. | $21.54 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $192.33 | 9 | E.R. Squibb & Sons, L.L.C. ($49.10) |
| 2023 | $206.65 | 9 | Novartis Pharmaceuticals Corporation ($101.12) |
| 2022 | $15.49 | 1 | PFIZER INC. ($15.49) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $77.93 | 4 | Seagen Inc. ($27.65) |
| 2018 | $78.35 | 4 | Takeda Pharmaceuticals U.S.A., Inc. ($21.77) |
| 2017 | $43.67 | 2 | Eisai Inc. ($23.67) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $24.60 | General |
| 10/29/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $24.50 | General |
| 07/23/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: Oncology | ||||||
| 04/10/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.51 | General |
| Category: Hematology | ||||||
| 03/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: Oncology | ||||||
| 01/23/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $31.22 | General |
| Category: Oncology | ||||||
| 12/12/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $32.73 | General |
| 11/01/2023 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $27.42 | General |
| Category: Oncology | ||||||
| 10/31/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Oncology | ||||||
| 10/26/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: Oncology | ||||||
| 07/18/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $29.95 | General |
| Category: Oncology | ||||||
| 06/07/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: Oncology | ||||||
| 04/25/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: Oncology | ||||||
| 04/20/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Oncology | ||||||
| 04/17/2023 | Lilly USA, LLC | RETEVMO (Drug) | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: Oncology | ||||||
| 12/13/2022 | PFIZER INC. | ELIQUIS (Drug), COMIRNATY, PAXLOVID | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 09/21/2020 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $17.52 | General |
| Category: Oncology | ||||||
| 08/17/2020 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $27.65 | General |
| Category: Oncology | ||||||
| 07/14/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $17.06 | General |
| Category: Oncology | ||||||
| 01/21/2020 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Oncology | ||||||
| 12/11/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 64 | 3,400 | 53,100 | $3.5M | $792,037 |
| 2022 | 74 | 4,227 | 52,128 | $3.3M | $671,217 |
| 2021 | 67 | 4,020 | 40,357 | $2.5M | $506,827 |
| 2020 | 70 | 3,949 | 43,349 | $3.6M | $790,907 |
Total Patients
15,596
Total Services
188,934
Medicare Billing
$2.8M
Procedure Codes
275
All Medicare Procedures & Services
275 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 11 | 6,480 | $826,200 | $246,467 | 29.8% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 4,900 | $670,300 | $212,368 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 306 | 691 | $254,288 | $62,700 | 24.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 19 | 2,460 | $162,120 | $45,356 | 28.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 18 | 15,475 | $309,500 | $34,144 | 11.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 86 | 191 | $135,037 | $20,233 | 15.0% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 11 | 16 | $76,832 | $19,551 | 25.4% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 18 | 696 | $125,280 | $13,827 | 11.0% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 180 | $242,640 | $13,662 | 5.6% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 19 | 30 | $51,660 | $10,536 | 20.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 375 | 901 | $57,664 | $9,302 | 16.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 387 | 1,060 | $21,200 | $8,904 | 42.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 60 | $29,760 | $8,260 | 27.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 69 | 142 | $44,446 | $7,479 | 16.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 375 | 982 | $35,352 | $7,456 | 21.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 102 | 111 | $27,750 | $6,383 | 23.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 21 | 79 | $16,669 | $4,745 | 28.5% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 39 | 128 | $18,304 | $4,484 | 24.5% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 62 | 264 | $15,840 | $4,468 | 28.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 58 | 180 | $28,260 | $4,207 | 14.9% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 96 | 168 | $21,504 | $3,426 | 15.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $14,180 | $3,241 | 22.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 26 | 47 | $16,168 | $2,441 | 15.1% |
| 86320 | Immunologic analysis technique on serum | Office | 2023 | 52 | 80 | $8,640 | $2,321 | 26.9% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 35 | 13,500 | $27,000 | $2,220 | 8.2% |
About Dr. Demetrius Loukas, M.D
Dr. Demetrius Loukas, M.D is a Hematology & Oncology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154369775.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Demetrius Loukas, M.D has received a total of $626.34 in payments from pharmaceutical and medical device companies, with $192.33 received in 2024. These payments were reported across 30 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($597.36).
As a Medicare-enrolled provider, Loukas has provided services to 15,596 Medicare beneficiaries, totaling 188,934 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 275 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Austin, TX
- Active Since 06/04/2006
- Last Updated 03/03/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1154369775
Products in Payments
- KISQALI (Drug) $74.04
- BESREMI (Drug) $58.64
- PADCEV (Biological) $44.26
- ADCETRIS (Biological) $43.00
- PROMACTA (Drug) $29.95
- RETEVMO (Drug) $26.85
- Halaven (Drug) $23.67
- IBRANCE (Drug) $22.64
- NINLARO (Drug) $21.77
- TECENTRIQ (Biological) $21.54
- Zydelig (Drug) $20.00
- LIBTAYO (Biological) $19.24
- REBLOZYL (Biological) $18.51
- Lenvima (Drug) $17.52
- OPDIVO (Biological) $17.06
- SARCLISA (Biological) $16.02
- Vitrakvi (Drug) $15.70
- ELIQUIS (Drug) $15.49
- Victoza (Drug) $13.83
- DARZALEX (Biological) $12.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Austin
Dr. Debra Patt, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $109,909
Hematology & Oncology $109,909
Uttam Rao
Hematology & Oncology — Payments: $19,966
Hematology & Oncology $19,966
Dr. Allison Gorrebeeck, Md, MD
Hematology & Oncology — Payments: $5,624
Hematology & Oncology $5,624
Dr. Richard Helmer, M.d, M.D
Hematology & Oncology — Payments: $3,540
Hematology & Oncology $3,540
Vinod Kondragunta
Hematology & Oncology — Payments: $3,490
Hematology & Oncology $3,490
Dr. Shubhada Shrikhande, Md, MD
Hematology & Oncology — Payments: $1,469
Hematology & Oncology $1,469